Royal Bank of Canada Buys 7,818 Shares of Mesa Laboratories, Inc. $MLAB

Royal Bank of Canada boosted its stake in shares of Mesa Laboratories, Inc. (NASDAQ:MLAB) by 143.3% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 13,275 shares of the medical instruments supplier’s stock after purchasing an additional 7,818 shares during the period. Royal Bank of Canada owned about 0.24% of Mesa Laboratories worth $1,173,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Jacobs Levy Equity Management Inc. purchased a new stake in Mesa Laboratories during the 1st quarter valued at $335,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Mesa Laboratories by 4.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 3,068 shares of the medical instruments supplier’s stock worth $364,000 after buying an additional 143 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of Mesa Laboratories by 3.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 19,977 shares of the medical instruments supplier’s stock worth $2,370,000 after buying an additional 685 shares during the last quarter. American Century Companies Inc. grew its holdings in shares of Mesa Laboratories by 1.5% in the second quarter. American Century Companies Inc. now owns 13,431 shares of the medical instruments supplier’s stock worth $1,265,000 after acquiring an additional 194 shares during the period. Finally, Gamco Investors INC. ET AL bought a new stake in shares of Mesa Laboratories in the second quarter worth $370,000. Hedge funds and other institutional investors own 90.60% of the company’s stock.

Mesa Laboratories Stock Performance

MLAB opened at $119.15 on Friday. The firm has a market cap of $667.24 million, a P/E ratio of 141.85 and a beta of 0.92. Mesa Laboratories, Inc. has a 1-year low of $58.83 and a 1-year high of $121.90. The company has a 50 day simple moving average of $101.08 and a two-hundred day simple moving average of $97.04. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.79 and a quick ratio of 1.32.

Mesa Laboratories (NASDAQ:MLAB) last announced its quarterly earnings data on Monday, August 10th. The medical instruments supplier reported $2.68 EPS for the quarter. The firm had revenue of $60.14 million for the quarter. Mesa Laboratories had a net margin of 1.92% and a return on equity of 22.72%.

Mesa Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 15th. Shareholders of record on Monday, August 31st will be issued a dividend of $0.16 per share. The ex-dividend date of this dividend is Monday, August 31st. This represents a $0.64 dividend on an annualized basis and a yield of 0.5%. Mesa Laboratories’s dividend payout ratio (DPR) is currently 76.19%.

Insider Buying and Selling at Mesa Laboratories

In other Mesa Laboratories news, CEO Siddhartha Kadia bought 7,093 shares of the business’s stock in a transaction that occurred on Thursday, August 13th. The stock was purchased at an average price of $112.80 per share, for a total transaction of $800,090.40. Following the completion of the transaction, the chief executive officer owned 7,093 shares of the company’s stock, valued at $800,090.40. This trade represents a ? increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director R Tony Tripeny bought 900 shares of the business’s stock in a transaction that occurred on Thursday, August 13th. The shares were acquired at an average price of $113.69 per share, with a total value of $102,321.00. Following the transaction, the director directly owned 6,298 shares of the company’s stock, valued at $716,019.62. This represents a 16.67% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders sold 15,370 shares of company stock valued at $1,570,213. 2.80% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of research firms have weighed in on MLAB. Weiss Ratings raised Mesa Laboratories from a “sell (d)” rating to a “hold (c-)” rating in a report on Tuesday, August 11th. Wells Fargo & Company boosted their price target on Mesa Laboratories from $94.00 to $110.00 and gave the company an “equal weight” rating in a research note on Friday, August 14th. Finally, Wall Street Zen lowered shares of Mesa Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 15th. Three investment analysts have rated the stock with a Hold rating, Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $110.00.

Mesa Laboratories Profile

Mesa Laboratories, Inc (NASDAQ: MLAB) is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company’s product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.